Aryeh Jason’s $0‑Price RSU Grant Signals Long‑Term Confidence at Ligand Pharmaceuticals
Insider Aryeh Jason’s zero‑cost RSU purchase of 836 Ligand shares signals confidence in the drugmaker’s growth and offers investors a bullish insider signal amid strong 2026 performance.
3 minutes to read